Experimental and clinical psychopharmacology最新文献

{"title":"Hippocampal gray matter volume in young adulthood varies with adolescent alcohol use.","authors":"Juliann B Purcell, Nathaniel G Harnett, Sylvie Mrug, Marc N Elliott, Susan Tortolero Emery, Mark A Schuster, David C Knight","doi":"10.1037/pha0000722","DOIUrl":"10.1037/pha0000722","url":null,"abstract":"<p><p>Adolescent substance use is linked with negative future outcomes (e.g., depression, anxiety, substance use disorder). Given that the brain undergoes significant maturation during adolescence, this developmental period may represent a time of particular vulnerability to substance use. Neuroimaging research has largely focused on heavy or binge patterns of substance use; thus, relatively less is known about the neural impact of a broader range of adolescent substance use. Characterizing the neural impact of a broader range of adolescent substance use may inform prevention and treatment efforts. The present study investigated relationships between adolescent substance use trajectories (i.e., alcohol, tobacco, and cannabis) and gray matter volume in young adulthood. Substance use was assessed in 1,594 participants at ages 11, 13, 16, and 19. Following the last assessment, 320 participants completed a single magnetic resonance imaging session to assess brain gray matter volume. Latent growth curve models were used to estimate growth parameters characterizing alcohol, tobacco, and cannabis use trajectories for each participant. These growth parameters (i.e., intercept, linear slope, and quadratic slope) were then used as predictors of gray matter volume. The gray matter volume of the hippocampus was positively associated with age 14 alcohol use (i.e., intercept) but not other trajectories (i.e., progression or acceleration) or substances (tobacco or cannabis). These results provide new insight into the neural impact of distinct adolescent alcohol, tobacco, and cannabis use trajectories, which may help to refine prevention and treatment efforts. (PsycInfo Database Record (c) 2024 APA, all rights reserved).</p>","PeriodicalId":12089,"journal":{"name":"Experimental and clinical psychopharmacology","volume":null,"pages":null},"PeriodicalIF":2.4,"publicationDate":"2024-10-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"140944318","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":3,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Prospective associations of behavioral economic demand for cannabis and alcohol with simultaneous cannabis and alcohol use among young adults.","authors":"Sophie G Coelho, Christian S Hendershot, Jeffrey D Wardell","doi":"10.1037/pha0000725","DOIUrl":"10.1037/pha0000725","url":null,"abstract":"<p><p>Behavioral economic demand for cannabis and alcohol is robustly associated with cannabis use and alcohol use, respectively. However, few studies have examined the contributions of cannabis and alcohol demand to simultaneous cannabis and alcohol use, which is common among young adults. We examined prospective associations of cannabis demand and alcohol demand with propensity for simultaneous use (broadly defined as using both cannabis and alcohol in the same day) and with cannabis and alcohol consumption during simultaneous use days among young adults. Young adults reporting simultaneous use (<i>N</i> = 107) completed a Marijuana Purchase Task assessing cannabis demand and an Alcohol Purchase Task assessing alcohol demand. They then completed daily smartphone surveys over 21 days assessing cannabis and alcohol use. Multilevel models revealed that higher cannabis demand (i.e., higher <i>O</i>_max, <i>P</i>_max, and intensity; lower elasticity) was uniquely associated with greater propensity for simultaneous use relative to nonuse. In addition, higher alcohol demand (lower elasticity) was uniquely associated with greater propensity for simultaneous use relative to cannabis-only use, and higher cannabis demand (higher break point and intensity, lower elasticity) was uniquely associated with greater propensity for simultaneous use relative to alcohol-only use. Furthermore, in models limited to simultaneous use days, greater cannabis demand (higher <i>O</i>_max, lower elasticity) and lower alcohol demand (higher elasticity) were uniquely associated with greater overall cannabis flower consumption, and higher alcohol demand (higher <i>O</i>_max, lower elasticity) was uniquely associated with greater overall alcohol consumption. Results suggest that individual differences in cannabis and alcohol demand may contribute to simultaneous cannabis and alcohol use behaviors in a substance-specific pattern. Furthermore, cannabis demand may more strongly drive the tendency to engage in simultaneous use (vs. nonuse) relative to alcohol demand. (PsycInfo Database Record (c) 2024 APA, all rights reserved).</p>","PeriodicalId":12089,"journal":{"name":"Experimental and clinical psychopharmacology","volume":null,"pages":null},"PeriodicalIF":2.4,"publicationDate":"2024-10-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"141426665","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":3,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Assessment of human abuse potential of an unflavored, sucralose-sweetened electronic cigarette in combustible cigarette smokers.","authors":"Sarah F Maloney, Cosima Hoetger, Rose S Bono, Rebecca Lester Scholtes, Madison Combs, Nareg Karaoghlanian, Thokozeni Lipato, Alison Breland, Thomas Eissenberg","doi":"10.1037/pha0000720","DOIUrl":"10.1037/pha0000720","url":null,"abstract":"<p><p>Despite the popularity of electronic cigarettes (ECIGs), limited research has examined the role of sweeteners, independent of other flavors, in shaping ECIG human abuse potential (HAP). This study examined the effects of sucralose and nicotine in unflavored ECIG liquid solutions to provide a basic understanding of the effects of sweeteners on ECIG HAP compared to combustible cigarettes. Individuals who smoked cigarettes daily (<i>N</i> = 14) completed five within-subject, Latin-square ordered study sessions that differed by product used: (a) own-brand combustible cigarettes (OB), (b) 0 mg/mL nicotine, unsweetened liquid, (c) 0 mg/mL nicotine, sucralose-sweetened liquid, (d) 15 mg/mL nicotine, unsweetened liquid, and (e) 15 mg/mL nicotine, sucralose-sweetened liquid. Participants completed subjective questionnaires and behavioral tasks following a 10-puff directed use bout during which puff topography was measured, and blood was sampled for later measurement of plasma nicotine concentration. On average, the OB condition had a greater increase in plasma nicotine concentration and produced more pronounced subjective effects compared to the ECIG conditions. The 15 mg/mL nicotine ECIGs delivered significantly more nicotine and produced greater drug effects and reductions in tobacco abstinence symptoms than the 0 mg/mL nicotine ECIGs. Sucralose-containing solutions increased ECIG product appeal, puff duration, and puff volume during the 10-puff directed bout. Findings revealed greater HAP for OB cigarettes relative to all ECIGs tested and suggest that adding sucralose and nicotine elevates ECIG HAP via different mechanisms; sucralose appears to influence HAP through product appeal, while nicotine influences HAP through drug effects and tobacco/nicotine abstinence symptom suppression. (PsycInfo Database Record (c) 2024 APA, all rights reserved).</p>","PeriodicalId":12089,"journal":{"name":"Experimental and clinical psychopharmacology","volume":null,"pages":null},"PeriodicalIF":2.4,"publicationDate":"2024-10-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"141179390","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":3,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"A meta-analysis on polymorphic trait of taste perception mediated by TAS2R38 genotype.","authors":"Vishnu Shivam","doi":"10.1037/pha0000728","DOIUrl":"10.1037/pha0000728","url":null,"abstract":"<p><p>The objective of this study is to review the association of TAS2R38 polymorphisms and taste phenotypes to bitter compounds (phenylthiocarbamide [PTC]/propylthiouracil [PROP]), and its association among persons who drink alcohol and individuals with smoking behavior. A literature search was carried out in PubMed, ScienceDirect, Cochrane, and Wiley online library databases using the keyword \"(Bitter taste receptor genes OR TAS2R38) AND (PROP OR propylthiouracil) AND (PTC OR phenylthiocarbamide),\" \"(Bitter taste receptor genes OR TAS2R38) AND (alcohol),\" \"(Bitter taste receptor genes OR TAS2R38) AND (tobacco OR smoker)\" to find articles evaluating the association of taste phenotypes and TAS2R38 polymorphisms, and its association among persons who drink alcohol and individuals with smoking behavior. The analysis show that TAS2R38 taster genotype (proline-alanine-valine [PAV] allele) was significantly (OR, 5.88; CI [3.87, 8.95], <i>p</i> < .001) associated with taster phenotype for bitter compounds (PTC/PROP), and TAS2R38 nontaster genotype (alanine-valine-isoleucine allele) was significantly (OR, 6.73; CI [4.57, 9.90], <i>p</i> < .001) associated with nontaster phenotype for bitter compounds. Further, TAS2R38 taster genotypes (PAV homozygotes and heterozygotes) were significantly associated with higher alcohol intake (OR, 5.15; 95% CI [2.66, 9.98]; <i>p</i> < .001) and among individuals with smoking behavior (OR, 1.73; 95% CI [1.24, 2.42]; <i>p</i> = .001). This suggests that TAS2R38 single nucleotide polymorphisms can be identified by clinically assessing taste phenotype status for bitter compounds and can be used as a potential therapeutic target in the prevention and treatment of harmful higher alcohol intake and smoking behavior. (PsycInfo Database Record (c) 2024 APA, all rights reserved).</p>","PeriodicalId":12089,"journal":{"name":"Experimental and clinical psychopharmacology","volume":null,"pages":null},"PeriodicalIF":2.4,"publicationDate":"2024-10-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"141179328","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":3,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Constraining electronic nicotine delivery systems (ENDS) nicotine dose by controlling nicotine flux at a limited puff duration.","authors":"Alison J Patev, Madison Combs, Nicoleta Gaitan, Nareg Karaoghlanian, Thokozeni Lipato, Thomas Eissenberg, Alison Breland","doi":"10.1037/pha0000719","DOIUrl":"10.1037/pha0000719","url":null,"abstract":"<p><p>Nicotine flux, the rate of electronic nicotine delivery system (ENDS) nicotine emission, is important in determining ENDS abuse liability. However, flux does not account for user behavior, including puff duration. Along with nicotine flux, puff duration limits the dose of nicotine that can be inhaled. Controlling both flux and puff duration allows regulators to constrain nicotine dose effectively. This study examined the effects of differing ENDS nicotine fluxes (by manipulating liquid nicotine concentration and holding device power constant), with user puff duration limited to 2 s. Participants (<i>N</i> = 32) completed four sessions, each session differing by nicotine flux (no flux, low flux, cigarettelike flux, and high flux conditions). Participants completed two ENDS use bouts in each session while puff duration was limited to 2 s. Plasma nicotine concentration, heart rate, and subjective effects were measured. At higher flux, higher plasma nicotine concentration and higher heart rate were observed. Moreover, higher fluxes decreased ratings of craving and urge to use nicotine and increased positive subjective effects, such as calmness. This study demonstrates that by manipulating nicotine flux and limiting puff duration, nicotine dose can be controlled. Subsequent research should demonstrate the effects of manipulating puff duration systematically. Results underscore the importance of targeting both flux and puff duration for ENDS regulation, intended to reduce abuse liability while maintaining the potential to facilitate transitions from cigarettes to ENDS. (PsycInfo Database Record (c) 2024 APA, all rights reserved).</p>","PeriodicalId":12089,"journal":{"name":"Experimental and clinical psychopharmacology","volume":null,"pages":null},"PeriodicalIF":2.4,"publicationDate":"2024-10-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"141179403","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":3,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Lower motivation for rewarded mental effort in tobacco dependence.","authors":"Alexander Soutschek, Charlotte E Wittekind","doi":"10.1037/pha0000726","DOIUrl":"10.1037/pha0000726","url":null,"abstract":"<p><p>Tobacco dependence is characterized by decision-making impairments, which may increase the risk of smoking relapse by lowering the capacity to resist the immediate gratification of nicotine consumption. Because controlling one's desires for immediate rewards is experienced as effortful, aversion to effortful control processes may also influence the prospects of successful smoking cessation. We therefore tested whether persons who smoke, compared with persons who do not smoke, show a lower willingness to engage in goal-directed mental effort. Thirty-seven persons who smoke and 38 persons who do not smoke performed a decision task requiring choices on whether to exert a demanding attention task for monetary rewards. Using state-of-the-art drift-diffusion modeling, we found that persons who smoke showed a stronger starting bias toward effort-free rewards. Taken together, our process model approach allowed us to identify the subcomponents of the decision process underlying the stronger aversion against mental effort in tobacco dependence, which may contribute to altered decision making by lowering the motivation to engage in effortful control processes when trying to suppress the desire for nicotine consumption. (PsycInfo Database Record (c) 2024 APA, all rights reserved).</p>","PeriodicalId":12089,"journal":{"name":"Experimental and clinical psychopharmacology","volume":null,"pages":null},"PeriodicalIF":2.4,"publicationDate":"2024-10-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"141179411","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":3,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Episodic future thinking reduces delay discounting among persons who use e-cigarettes.","authors":"B Eric Turnquist, Laura M Juliano","doi":"10.1037/pha0000745","DOIUrl":"https://doi.org/10.1037/pha0000745","url":null,"abstract":"<p><p>There has been an alarming increase in e-cigarette dependence among young adults, many of whom would like to quit vaping nicotine but are finding it difficult to do so. Episodic future thinking (EFT), a cognitive intervention involving imagining future events, has been shown to reduce cigarette craving, demand intensity, and self-administration among cigarette smokers but has not been tested with e-cigarette users. This study tested if a brief EFT intervention decreases delay discounting and smoking choice using a within-subjects experimental design administered via Zoom. Daily young adult e-cigarette users attended a baseline session and two counterbalanced experimental sessions: (a) EFT in which participants preexperienced and described positive future events and (b) standardized episodic thinking, a control intervention in which participants described their experiences watching three short videos. Measures of craving, mood, and delay discounting across three commodities: Money, e-cigarette products, and food were completed pre- and postmanipulation. As predicted, monetary delay discounting showed a greater decrease following EFT relative to standardized episodic thinking (<i>p</i> = .006; η<i>_p</i>² = .229). There were no effects on craving or mood. Participants also completed a 40-min vaping versus money choice task. Approximately 70% of participants chose to abstain for the full 40 min after EFT compared to 60% after the control condition, a nonsignificant difference (<i>p</i> = .184). Additional research is needed to support the efficacy of EFT as an intervention for helping e-cigarette users increase their ability to abstain. The study demonstrates the feasibility of conducting experimental research on e-cigarettes in a virtual setting. (PsycInfo Database Record (c) 2024 APA, all rights reserved).</p>","PeriodicalId":12089,"journal":{"name":"Experimental and clinical psychopharmacology","volume":null,"pages":null},"PeriodicalIF":2.4,"publicationDate":"2024-09-26","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"142344245","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":3,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Oxytocin as a treatment for alcohol use disorder and heavy drinking: A narrative review.","authors":"Kriti Rastogi, Elise M Weerts, Jennifer D Ellis","doi":"10.1037/pha0000741","DOIUrl":"https://doi.org/10.1037/pha0000741","url":null,"abstract":"<p><p>Oxytocin is increasingly being studied for treating symptoms of alcohol use disorders and heavy drinking behavior. The neuropeptide oxytocin facilitates social relationships and modulates the body's stress response by strengthening coping mechanisms and reducing anxiety. Relatedly, oxytocin is also thought to play a role in processes associated with craving and withdrawal from alcohol. This review aims to primarily provide an overview of preclinical and clinical literature on the applications of oxytocin in alcohol use, and additionally discuss a framework for types of trials and the variety of parameters that affect different study designs. A review of the existing literature in this area suggests that while low dosages of oxytocin do not affect drinking behavior and tolerance, higher dosages taken prior to alcohol exposure have varying behavioral and physiological results. Depending on quantity and timing, oxytocin treatments resulted in declines in withdrawal symptoms and alcohol self-administration in preclinical studies and may decrease neural cue reactivity and withdrawal symptoms in clinical studies. Current ongoing trials are expanding on this work to thoroughly explore clinical applications of oxytocin. (PsycInfo Database Record (c) 2024 APA, all rights reserved).</p>","PeriodicalId":12089,"journal":{"name":"Experimental and clinical psychopharmacology","volume":null,"pages":null},"PeriodicalIF":2.4,"publicationDate":"2024-09-19","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"142282524","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":3,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Residual and enduring effects of cannabis use on cognitive and psychomotor function: A study of adults during unrestricted cannabis use, short-term abstinence, and protracted abstinence.","authors":"Carson O Burke, Sophie Boutouis, Jeffrey S Spence, Francesca M Filbey","doi":"10.1037/pha0000732","DOIUrl":"10.1037/pha0000732","url":null,"abstract":"<p><p>The impact of cannabis on cognitive and psychomotor function is important to understand, given the role of the endocannabinoid system in these critical processes. The literature has shown robust acute negative effects of cannabis on cognition and psychomotor skills during intoxication, and to a lesser degree, persisting effects following short-term abstinence up to 4 weeks. However, whether these decrements resolve after long-term cessation of use remains unclear. We evaluated cognitive and psychomotor function in 31 adults with current cannabis use during unrestricted use (UNR) and after a 3-day abstinence (RES), 23 adults with former cannabis use (> 90 days abstinent; FU), and 58 nonusing controls (CON) using the cognition and motor batteries of the National Institutes of Health Toolbox. Linear mixed models showed no significant differences in cognitive and motor performance between UNR, RES, and FU groups. Group effects emerged such that CON outperformed UNR on the Oral Reading Recognition Test, and CON outperformed both UNR and RES on the Picture Vocabulary Test. In terms of psychomotor function, FU, RES, and UNR performed better than CON on the Grip Strength Test. In this comprehensive examination of cognitive and psychomotor performance in adults with cannabis use with 3 days to > 90 days of abstinence, our results indicated that the cognitive impacts of chronic, heavy cannabis use are observable during short-term abstinence but remit after > 90 days of abstinence. This highlights widespread impacts of cannabis use abstinence across cognitive and psychomotor domains. Future studies are needed to evaluate whether these effects are also observable with use reduction, as opposed to abstinence. (PsycInfo Database Record (c) 2024 APA, all rights reserved).</p>","PeriodicalId":12089,"journal":{"name":"Experimental and clinical psychopharmacology","volume":null,"pages":null},"PeriodicalIF":2.4,"publicationDate":"2024-08-29","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"142105792","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":3,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Opioid Protective Behavioral Strategies Scale (OPBSS): Development and psychometric evaluation.","authors":"Margo C Hurlocker, Matthew R Pearson","doi":"10.1037/pha0000738","DOIUrl":"https://doi.org/10.1037/pha0000738","url":null,"abstract":"<p><p>Protective behavioral strategies (PBS) are behaviors that individuals use to mitigate harm related to risky behaviors. Though measures have been validated to assess alcohol- and cannabis-specific PBS use, an opioid-specific PBS measure has yet to be validated. The present study developed and validated a tool to assess the extent of PBS employed by individuals who use licit and/or illicit opioids. We recruited a community sample of adults who endorsed past-month opioid use (<i>n</i> = 345) via online platforms to complete a baseline survey, and 277 participants (80.2%) also completed the 1-month follow-up survey. From PBS measures of other substances, harm reduction strategies found in the literature, and expert feedback, we developed the 60-item Opioid Protective Behavioral Strategies Scale (OPBSS). We removed 14 items based on item and exploratory factor analyses, resulting in 46 retained items. A two-factor solution was supported: strategies focused on managing opioid use (Controlled Opioid Use) and preventing opioid-related harm (Serious Harm Reduction). The OPBSS subscales demonstrated high internal consistencies, fair-to-excellent test-retest reliability, significant positive associations with PBS measures for other substances, and robust associations with risky opioid use and opioid-related negative consequences, both concurrently and prospectively when controlling for other opioid characteristics. The 46-item OPBSS has promising psychometric properties. Importantly, more opioid PBS predicted less risky opioid use and related consequences, suggesting that opioid PBS may be a beneficial opioid prevention effort. However, additional psychometric work is needed to determine which PBS are most suitable for populations with distinct opioid use patterns. (PsycInfo Database Record (c) 2024 APA, all rights reserved).</p>","PeriodicalId":12089,"journal":{"name":"Experimental and clinical psychopharmacology","volume":null,"pages":null},"PeriodicalIF":2.4,"publicationDate":"2024-08-29","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"142105791","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":3,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}